Search bioRxiv⌕ Search

Biology subjects

Greisen, P.

Publications and source records attributed to Greisen, P..

4 recordsLinked to original sources

Biomolecular design through latent reasoning with RFD4-Proteina

Biomolecular design requires finding chemically and geometrically compatible arrangements of interacting atoms and molecules. The complexity of problems which can be tackled by deep learning design models is limited by both the molecular landscape they encompass and their ability to explore that landscape effectively. Here we introduce RFD4-Proteina, which addresses these limitations through intrinsic and extrinsic reasoning within a shared chemical and conformational latent space. The latent space encompasses standard and modified amino acids, sugars, DNA, and RNA, with force-field supervision favoring physically plausible atomic reconstructions. Within this space, intrinsic reasoning uses recurrent refinement to adaptively allocate computation, while extrinsic reasoning guides search with arbitrary constraints such as energetic or geometric criteria. Across in silico protein design benchmarks, RFD4-Proteina achieves higher design success rates at greater generation throughput than all previous methods evaluated, with further gains from conformational flexibility, recurrent refinement, and search. The same model performs equivalently to or better than state-of-the-art specialist methods for side-chain packing, sequence design, conformational sampling, and design refinement. We demonstrate the power and versatility of RFD4-Proteina experimentally by designing specific and cross-reactive binders to therapeutically relevant targets, recognizing phosphorylations, controlling glycosylation, and creating enzymes that catalyze both bond-breaking and bond-forming reactions, including a first proof-of-concept demonstration of a de novo designed enzyme for active pharmaceutical ingredient synthesis. By unifying diverse chemistry, conformational flexibility, and scalable reasoning in a single physically grounded latent space, RFD4-Proteina expands the frontier of biomolecular design.

bioengineering↗

De Novo Computational Design of VHH Nanobodies Against LGR5

VHH discovery traditionally relies on animal immunization or large-scale library screening, methods that are slow, costly, and often ineffective for challenging targets such as GPCRs. We present a fully de novo computational pipeline for epitope-directed VHH design, integrating generative backbone modeling, deep learning-based sequence optimization, and iterative experimental feedback. Using LGR5 as a model, we progressed from in silico design to functional binders without structural templates. Across three design-test-learn cycles, millions of candidates were reduced to epitope-specific binders with nanomolar affinity and high thermal stability (melting temperature [Tm] > 65 {degrees}C). Cryogenic electron microscopy (cryo-EM) confirmed atomic-level agreement (RMSD {approx} 2.2 [A]). This structure-validated approach accelerates timelines, reduces cost, and is broadly applicable to GPCRs and other membrane proteins, enabling "on-demand" therapeutic antibody generation.

bioengineering↗

AI-guided design of common light chains to enable manufacturable bispecific antibodies

Bispecific antibodies (BsAbs) offer therapeutic advantages but face manufacturing bottlenecks from light chain mispairing, which can generate a substantial fraction of incorrect products and increase manufacturing complexity and cost of goods. Common light chains (cLC) eliminate mispairing, yet existing approaches require screening thousands of variants per target. We present an AI-driven framework that computationally designs cLCs through structure-guided pairing of non-cognate VH-VL interfaces, reducing experimental screening by three orders of magnitude. The platform successfully engineers therapeutic antibodies lacking experimental structures, expanding applicability beyond crystallographic databases. Among 10 therapeutic targets, we successfully generated designs for 7 targets, comprising 55 unique BsAb pairs. Of these, 43.6% (24/55) were successfully as BsAb cLCs. Three bispecific antibodies reached production-ready specifications: >90% purity and 1.6-1.8 g/L titers. This platform democratizes bispecific antibody development, expanding access beyond well-resourced programs.

bioengineering↗

Computational Design of Soluble CCR8 Analogues with Preserved Antibody Binding

G protein-coupled receptors (GPCRs) represent the largest class of drug targets, yet their membrane-embedded nature poses significant challenges for structural studies and therapeutic development. Here, we report the successful computational design and experimental validation of soluble CCR8 analogues that maintain native antibody binding properties. Using an integrated pipeline combining ProteinMPNN-sol sequence design, and structure-based filtering, we generated 13 CCR8 analogues from 272 initial designs across three N-terminal truncation strategies. Experimental validation confirmed 62% success rate (8/13 designs) with protein yields of 1.19-73.72 mg/L in aqueous buffer, representing a significant improvement over traditional membrane protein production method. Surface plasmon resonance analysis demonstrated that all analogues retained mAb1 binding with dissociation constants ranging from 77-857 nM, comparable to wild-type CCR8 (KD = 190 nM). Despite extensive sequence divergence (10-13% identity with wild-type CCR8), structural integrity was preserved as evidenced by binding affinity maintenance and computational structural validation. This work demonstrates the feasibility of computationally designing functional soluble analogues of challenging membrane proteins, with implications for accelerating drug discovery, antibody development, and structural biology studies. Our approach addresses critical limitations in membrane protein accessibility while preserving native epitope presentation, opening new avenues for therapeutic target characterization and binder discovery.

bioengineering↗